MD | Jotup

EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

Retrieved on:

星期三, 四月 10, 2024

Q&A, Associate, Oncology, Internet, Doctor of Philosophy, Spacecraft, MD, AACR, HPHA, Phase, ADC, BST, Hematology, ATAC, Annual general meeting

Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.

Key Points:

Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.
The event will provide information on Heidelberg Pharma’s lead clinical ATAC product candidate HDP-101 targeting relapsed and refractory multiple myeloma as well as its proprietary ADC toolbox and therapeutic product pipeline.
Attendees will have the opportunity to participate in a live Q&A session at the end of the presentation or submit questions in advance of the event.
For further information on the R&D webinar, or to register your interest, please contact Optimum Strategic Communications at [email protected] or register using the link below:

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on:

星期三, 四月 10, 2024

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points:

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

Powerful Medical's AI Breakthrough Marks a New Dawn in Heart Attack Diagnostics with EIC Support Doubles Sensitivity in Identifying Acute Coronary Occlusion on 12-Lead ECG

Retrieved on:

星期一, 三月 18, 2024

European Innovation Council, Longevity, Medicine, Cardiology, Patient, Splenic infarction, MD, EIC, Accelerator, European Investment Bank, Heart, EIB, FDA, Health, Medical device

With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.

Key Points:

With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.
At the core of its mission, Powerful Medical introduces the PMcardio platform, a CE-certified medical device leveraging proprietary AI to analyze electrocardiograms (ECGs) with remarkable precision.
This platform is capable of diagnosing heart attacks — specifically, occlusion myocardial infarctions — significantly earlier and with double the sensitivity compared to the current standard of care.
- Robert Herman, MD, Chief Medical Officer
As Powerful Medical begins its Series A fundraising, the EIC Accelerator's grant and investment endorse the company's vision and technology.

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Retrieved on:

星期二, 四月 9, 2024

MD, MIT, Patent, Composition, PASTE, PGI, DNA, State, United States patent law

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Key Points:

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
“Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

Retrieved on:

星期二, 四月 9, 2024

HER2, ILD, CPI, Survival, Progression-free survival, Central nervous system, Patient, CNS, History, Death, Eribulin, Spacecraft, MD, CBR, TPC, EMBRACE, Life, BCT, AACR, TSX, Therapy, Breast cancer, Safety, Poster, CMO, PFS, ADC, PD-1, Pharmaceutical industry

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.

Key Points:

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on:

星期二, 四月 9, 2024

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points:

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Retrieved on:

星期二, 四月 9, 2024

Antigen presentation, TLS, Survival, Immunotherapy, Patient, Neoplasm, Tumor microenvironment, Observation, Cancer, Doctor of Philosophy, MD, AACR, Therapy, Drug development, Poster, CADL, Pharmaceutical industry

TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity.

Key Points:

TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity.
The presentation describes the development of an investigational TLS-inducing multimodal therapeutic using the enLIGHTEN™ Discovery Platform.
The enLIGHTEN™ Advanced Analytics suite was applied to immune checkpoint inhibitor-treated patient datasets, and the predicted payload components included factors regulating the development of TLS.
“The enLIGHTEN™ Discovery Platform enables the generation of multimodal agents through the integration of artificial intelligence-driven payload combinations into programmable vectors.

Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024

Retrieved on:

星期二, 四月 9, 2024

Device, Intraocular lens, IOL, CDRH, Health equity, Partnership, Patient, SAN, Research, American Academy, Manuscript, MD, ENT, Quality, Safety, FDA, Cataract, Food, Medicine, Dentistry

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.

Key Points:

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.
“The results of this study underscore the transformative potential of high-quality, curated real-world data in generating real-world evidence to enhance treatments and improve patients’ lives,” said Sujay Jadhav, CEO of Verana Health.
“We thank the FDA for the opportunity to lead this study, and we extend our appreciation to the Academy for its partnership.
Verana Health utilized its clinician-directed and artificial intelligence-enhanced population health data engine, VeraQ ®, to analyze curated, de-identified IRIS Registry data on pediatric cataract surgeries, amplifying the depth and accuracy of the study's insights.

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Retrieved on:

星期二, 四月 9, 2024

Diagnosis, Biopsy, Fatty liver disease, Cirrhosis, Exercise, F2, Patient, Prescription, MD, Diet, Fibrosis, Pharmacy, NASH, Therapy, FDA, THR, JD

I can finally tell my appropriate patients with moderate to advanced fibrosis that we have an approved treatment to help improve fibrosis and resolve NASH.

Key Points:

I can finally tell my appropriate patients with moderate to advanced fibrosis that we have an approved treatment to help improve fibrosis and resolve NASH.
Madrigal is committed to helping appropriate patients who may benefit from Rezdiffra access the medication through the Madrigal Patient Support program.
This program is designed to help patients navigate insurance and affordability challenges and provide co-pay support for eligible patients.
Madrigal has also established a patient assistance program (PAP) to help patients with no insurance access Rezdiffra.

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on:

星期二, 四月 9, 2024

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points:

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.